Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefixime + metronidazole is a combination of two antibiotics used to treat mixed bacterial infections, particularly those involving both aerobic and anaerobic bacteria. Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis, leading to cell lysis and death. It is primarily effective against Gram-negative bacteria and some Gram-positive organisms[3]. Metronidazole is a nitroimidazole antibiotic that disrupts DNA synthesis in susceptible anaerobic bacteria and certain protozoa, resulting in cell death[6][9]. This combination may be used for conditions such as complicated intra-abdominal infections or for Helicobacter pylori eradication when both aerobic and anaerobic coverage are needed[2]. The drugs act via different mechanisms but together provide broad-spectrum antibacterial activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefixime + metronidazole.